Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors by Takashi Ueno, Yukiko Miyajima, Ishani Landry, Bojan Lalovic, Edgar Schuck

Connect to this object online.

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant by Ishani Landry, Jagadeesh Aluri, Nancy Hall, Dinesh Kumar, Satish Dayal, Margaret Moline, Larisa Reyderman

Connect to this object online.

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant by Satish Dayal, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Margaret Moline, Larisa Reyderman, Ishani Landry

Connect to this object online.

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant by Ishani Landry, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Satish Dayal, Margaret Moline, Larisa Reyderman

Connect to this object online.

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease by Seiichi Hayato, Osamu Takenaka, Sree Harsha Sreerama Reddy, Ishani Landry, Larisa Reyderman, Akihiko Koyama, Chad Swanson, Sanae Yasuda, Ziad Hussein

Connect to this object online.